Tapinarof, however, offers a potential solution by improving the skin barrier, reducing inflammation and relieving itch ...

US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 11, 2025, 16:00 Hrs ...

Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR) announced today that its drug candidate, rezpegaldesleukin, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ...

Atopic dermatitis is a chronic inflammatory skin disease affecting a growing number of people worldwide. Marked by persistent ...

Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial intelligence (AI)-powered wearable sensor that delivered haptic feedback on sleep ...

Individuals on immunosuppressants should discontinue them prior to patch testing, if at all possible, to avoid tarnishing the test results, according to updated guidelines from the North American ...

Long-term lebrikizumab was effective for atopic dermatitis treatment in patients who did not have adequate response to short-term treatment.

An artificial intelligence (AI)-enabled hand sensor delivering closed-loop haptic feedback appeared to be an effective ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...